Morgan Stanley reiterated their overweight rating on shares of UnitedHealth Group (NYSE:UNH – Get Rating) in a report published on Wednesday morning, Stock Target Advisor reports. Morgan Stanley currently has a $587.00 target price on the healthcare conglomerate’s stock.
UNH has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft lifted their target price on UnitedHealth Group from $569.00 to $615.00 and gave the company a buy rating in a research note on Tuesday, October 18th. Royal Bank of Canada boosted their price target on UnitedHealth Group from $588.00 to $592.00 and gave the stock an outperform rating in a research note on Monday, October 17th. StockNews.com began coverage on UnitedHealth Group in a research note on Wednesday, October 12th. They set a strong-buy rating on the stock. Credit Suisse Group boosted their price target on UnitedHealth Group from $579.00 to $590.00 and gave the stock an outperform rating in a research note on Monday, October 17th. Finally, Raymond James downgraded UnitedHealth Group from a strong-buy rating to an outperform rating and set a $615.00 target price for the company. in a report on Monday. Three equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, UnitedHealth Group currently has an average rating of Moderate Buy and an average target price of $595.11.
UnitedHealth Group Stock Performance
Shares of UnitedHealth Group stock opened at $529.71 on Wednesday. The stock’s fifty day moving average price is $523.65 and its 200-day moving average price is $515.60. UnitedHealth Group has a 12 month low of $438.21 and a 12 month high of $558.10. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 0.58. The firm has a market cap of $494.93 billion, a P/E ratio of 25.94, a P/E/G ratio of 1.63 and a beta of 0.75.
UnitedHealth Group Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 13th. Shareholders of record on Monday, December 5th will be issued a $1.65 dividend. This represents a $6.60 dividend on an annualized basis and a yield of 1.25%. The ex-dividend date is Friday, December 2nd. UnitedHealth Group’s payout ratio is presently 32.32%.
Insider Buying and Selling at UnitedHealth Group
In other news, CAO Thomas E. Roos sold 465 shares of the company’s stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $542.37, for a total transaction of $252,202.05. Following the completion of the transaction, the chief accounting officer now directly owns 34,786 shares of the company’s stock, valued at approximately $18,866,882.82. The sale was disclosed in a filing with the SEC, which is available at this link. 0.40% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in UNH. Price T Rowe Associates Inc. MD raised its stake in shares of UnitedHealth Group by 17.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 36,853,394 shares of the healthcare conglomerate’s stock worth $18,929,009,000 after buying an additional 5,556,335 shares during the period. Arrowstreet Capital Limited Partnership increased its position in shares of UnitedHealth Group by 1,682.4% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,691,542 shares of the healthcare conglomerate’s stock worth $1,372,606,000 after purchasing an additional 2,540,538 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of UnitedHealth Group by 60.4% during the first quarter. The Manufacturers Life Insurance Company now owns 5,009,284 shares of the healthcare conglomerate’s stock worth $2,580,442,000 after purchasing an additional 1,886,128 shares in the last quarter. Capital Research Global Investors increased its position in shares of UnitedHealth Group by 8.3% during the first quarter. Capital Research Global Investors now owns 19,273,691 shares of the healthcare conglomerate’s stock worth $9,829,129,000 after purchasing an additional 1,482,338 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of UnitedHealth Group by 28.3% during the first quarter. Invesco Ltd. now owns 6,018,008 shares of the healthcare conglomerate’s stock worth $3,069,002,000 after purchasing an additional 1,328,237 shares in the last quarter. 87.25% of the stock is owned by institutional investors and hedge funds.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services.
- Get a free copy of the StockNews.com research report on UnitedHealth Group (UNH)
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.